Abstract
BackgroundDespite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have